CANCER:

Esophageal Squamous Cell Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Esophageal Cancer (155)

Esophageal Adenocarcinoma (29)

Esophageal Cancer (155)

Esophageal Adenocarcinoma (29)

›

PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C1 ESMO 2022 - 3wk	atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks atezolizumab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression + CD8 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression + CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD8 expression	Esophageal Squamous Cell Carcinoma	CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
SLFN11 expression	Esophageal Squamous Cell Carcinoma	SLFN11 expression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cisplatin + 5-fluorouracil Sensitive : C3 ESMO 2022 - 3wk	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cisplatin + 5-fluorouracil Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B	tislelizumab Sensitive: B - Late Trials tislelizumab Sensitive : B
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B
PD-L1 overexpression	Esophageal Squamous Cell Carcinoma	PD-L1 overexpression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
NTRK3 fusion	Esophageal Squamous Cell Carcinoma	NTRK3 fusion	Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK2 fusion	Esophageal Squamous Cell Carcinoma	NTRK2 fusion	Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion	Esophageal Squamous Cell Carcinoma	NTRK1 fusion	Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
EGFR mutation	Esophageal Squamous Cell Carcinoma	EGFR mutation	Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C1 - Off-label afatinib Sensitive : C1	afatinib Sensitive: C1 - Off-label afatinib Sensitive : C1
HER-2 positive	Esophageal Squamous Cell Carcinoma	HER-2 positive	Esophageal Squamous Cell Carcinoma	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2	camrelizumab Sensitive: C2 – Inclusion Criteria camrelizumab Sensitive : C2
EGFR amplification	Esophageal Squamous Cell Carcinoma	EGFR amplification	Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2
NRG1 overexpression	Esophageal Squamous Cell Carcinoma	NRG1 overexpression	Esophageal Squamous Cell Carcinoma	AV-203 Sensitive: C3 – Early Trials AV-203 Sensitive : C3	AV-203 Sensitive: C3 – Early Trials AV-203 Sensitive : C3
NDRG1 overexpression	Esophageal Squamous Cell Carcinoma	NDRG1 overexpression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3
SGK1 overexpression	Esophageal Squamous Cell Carcinoma	SGK1 overexpression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3	cisplatin + 5-fluorouracil Resistant: C3 – Early Trials cisplatin + 5-fluorouracil Resistant : C3
AFAP1-AS1 overexpression	Esophageal Squamous Cell Carcinoma	AFAP1-AS1 overexpression	Esophageal Squamous Cell Carcinoma	FP Resistant: C3 – Early Trials FP Resistant : C3	FP Resistant: C3 – Early Trials FP Resistant : C3
TLR signature	Esophageal Squamous Cell Carcinoma	TLR signature	Esophageal Squamous Cell Carcinoma	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3
NDRG1-H	Esophageal Squamous Cell Carcinoma	NDRG1-H	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3
DKK1 overexpression	Esophageal Squamous Cell Carcinoma	DKK1 overexpression	Esophageal Squamous Cell Carcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3
DKK1 overexpression	Esophageal Squamous Cell Carcinoma	DKK1 overexpression	Esophageal Squamous Cell Carcinoma	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3
NFKB1 expression	Esophageal Squamous Cell Carcinoma	NFKB1 expression	Esophageal Squamous Cell Carcinoma	rivoceranib Sensitive: C3 – Early Trials rivoceranib Sensitive : C3	rivoceranib Sensitive: C3 – Early Trials rivoceranib Sensitive : C3
KDR expression	Esophageal Squamous Cell Carcinoma	KDR expression	Esophageal Squamous Cell Carcinoma	rivoceranib Sensitive: C3 – Early Trials rivoceranib Sensitive : C3	rivoceranib Sensitive: C3 – Early Trials rivoceranib Sensitive : C3
PD-L1 overexpression + CCL5 overexpression	Esophageal Squamous Cell Carcinoma	PD-L1 overexpression + CCL5 overexpression	Esophageal Squamous Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	toripalimab + surufatinib Sensitive: C3 – Early Trials toripalimab + surufatinib Sensitive : C3	toripalimab + surufatinib Sensitive: C3 – Early Trials toripalimab + surufatinib Sensitive : C3

Esophageal Squamous Cell Carcinoma

Associations(69)

Associations
(69)